[Federal Register: March 18, 2003 (Volume 68, Number 52)]
[Page 12912]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

Allergenic Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Allergenic Products Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held via videoconference and 
teleconference on April 8, 2003, from 1 p.m. to 3:30 p.m.
    Location: Food and Drug Administration, Bldg. 29B, conference rm. 
A, 8800 Rockville Pike, Bethesda, MD. This meeting will be held by 
video and teleconference. The public is welcome to attend the meeting 
at the onsite location. A speaker phone will be provided for public 
    Contact Person: William Freas or Jane Brown, Center for Biologics 
Evaluation and Research (HFM-71), Food and Drug Administration, 1401 
Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 12388. Please call the Information Line for 
up-to-date information on this meeting.
    Agenda: The committee will listen to updates on FDA activities 
relating to allergen extract standardization.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by April 3, 2003. 
Oral presentations from the public will be scheduled between 
approximately 2:15 p.m. and 3:15 p.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before April 4, 2003, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact William Freas, or 
Jane Brown at least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: March 10, 2003.
Linda Arey Skladany,
Associate Commissioner for External Relations.
[FR Doc. 03-6368 Filed 3-17-03; 8:45 am]